logo-loader
viewe-Therapeutics plc

e-Therapeutics hails 'striking productivity' of drug discovery engine

microscope_551a4713622ef.jpg

e-Therapeutics (LON:ETX) chief executive, professor Malcolm Young, hailed the “striking productivity” of its drug discovery engine as the firm delivered its end of term report.

Annual results reprised the significant progress made with its flagship cancer treatment ETS2101, which is currently in three separate clinical studies.

The life science firm, a pioneer of a technique called network pharmacology, confirmed that preliminary results from its US brain cancer trial will be available in the second quarter.

Phase IIb studies on its most advanced drug candidate, ETS6103 for depression, are set for completion in the second half, after which e-Therapeutics will look for a partner for it.

It also said it is assessing potential funding opportunities for ETX1153c, a fledgling treatment for the difficult to treat bacterial infection C. difficile.

In the lab, e-Therapeutics delivered a “dramatic acceleration of molecule selection and testing” during the year, with approximately 2,200 molecules, across six discovery projects, being assessed.

This compares to about 100 molecules in the previous year.

CEO Young said: "The investment and enhancements we have made over the past two years are paying dividends, not only with the number of molecules we can now screen, but in the ground-breaking yields we are observing.

“We have a wealth of active molecules to choose from to take forward into development.”

The financial results revealed that e-Therapeutics is well-funded with £33.8mln in the bank as at the end of the year.

The loss for 2014, largely an irrelevance for an emerging drugs developer, was £9.8mln.

Quick facts: e-Therapeutics plc

Price: 3.34 GBX

AIM:ETX
Market: AIM
Market Cap: £8.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

RNS

Holding(s) in Company

on 11/08/2019

Holding(s) in Company

on 10/29/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Holding(s) in Company

on 10/28/2019

Half-year Report

on 10/07/2019

Holding(s) in Company

on 09/17/2019

2 min read